Chrysalis lists among its partners early-stage biotechnology companies, contract research organizations, top-10 ...

PharmTech Group spoke with Andy Burns, vice-president of MDI Business Development at Kindeva, ahead of BIO 2025 to find out ...

The collaboration will focus on identifying pre-clinical candidates for high-priority targets, including a small molecule ...

The acquisition boosts BioNTech’s mRNA design and manufacturing capabilities, accelerating development of next-gen cancer ...

The warning letters deal with a range of violations involving items from personal hygienic products to mismarketed analgesics.

The agreement has been designed to offer a turnkey service to companies seeking faster time to market.

Elkedonia will develop first-in-class Elk1 inhibitors for treatment-resistant depression, targeting neuroplasticity without ...

NMPA’s Center for Drug Evaluation accepted Merck KGaA’s application for marketing authorization of pimicotinib as a Class 1 ...